세계의 첨단 치료제 의약품 아웃소싱 시장 규모 조사 : 서비스 유형별, 적응증별, 치료별, 단계별, 지역별 예측(2022-2032년)

The global advanced therapeutics pharmaceutical outsourcing market is valued approximately at USD 7,592.8 million in 2023 and is anticipated to grow with a healthy growth rate of more than 4.4% over the forecast period 2024-2032. Advanced therapeutics pharmaceutical outsourcing encompasses contracting specialized external partners to manage various stages of drug development and manufacturing for complex therapies. These advanced therapeutics include biologics, gene therapies, cell therapies, and personalized medicine. Outsourcing services range from research and development, clinical trials, regulatory compliance, to large-scale manufacturing. This approach allows pharmaceutical companies to leverage specialized expertise, state-of-the-art facilities, and innovative technologies without the significant capital investment required to develop these capabilities in-house. It also facilitates faster time-to-market, cost efficiencies, and the ability to focus on core competencies, ultimately enhancing patient access to cutting-edge treatments.

The rising complexity of advanced therapeutic modalities, such as gene editing, cell therapy, and mRNA-based drugs, demands specialized knowledge and sophisticated manufacturing capabilities. Pharmaceutical companies are increasingly partnering with outsourcing experts possessing advanced technical prowess to navigate the intricacies of these novel therapies. The burgeoning pipeline of advanced therapeutic products, driven by breakthroughs in biotechnology and genomics, has significantly amplified the demand for outsourcing services. As pharmaceutical companies concentrate on expanding their portfolios with innovative therapies, outsourcing emerges as a scalable and cost-effective solution for development and production.

The globalization of clinical trials for advanced therapeutics necessitates a network of partners with a global presence. Outsourcing facilitates access to diverse patient populations, regulatory environments, and manufacturing capabilities worldwide, supporting efficient and accelerated clinical development. A notable opportunity in the advanced therapeutics pharmaceutical outsourcing market lies in the expanding landscape of mRNA therapies. The increasing focus on mRNA therapies in cancer, infectious diseases, and genetic disorders presents a compelling opportunity for outsourcing partners. As pharmaceutical companies diversify their portfolios, outsourcing providers can offer specialized support in developing and manufacturing mRNA-based treatments. However, the advanced therapeutics pharmaceutical outsourcing market faces several challenges. One primary restrictive factor is the complex and evolving regulatory landscape governing advanced therapeutics. Regulatory agencies face challenges in establishing clear guidelines, as these therapies often involve cutting-edge technologies such as gene editing and cell therapy. This uncertainty can lead to delays in approvals and increase compliance burdens, impacting the speed at which outsourcing services can be leveraged.

The key regions considered for the global advanced therapeutics pharmaceutical outsourcing market study include North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America is expected to dominate the market during the forecast period, driven by its robust economy, widespread adoption of advanced technologies, and significant presence of leading AI software and system suppliers. The region's strong research and development initiatives and substantial investments in the oil and gas industry further fuel the demand for advanced therapeutics pharmaceutical outsourcing.

Major market players included in this report are:

• Croda International Plc
• Charles River Laboratories International, Inc.
• Catalent, Inc.
• QuintilesIMS (IQVIA)
• Parexel International Corporation
• ICON plc
• PPD, Inc. (Thermo Fisher Scientific)
• LabCorp (Laboratory Corporation of America Holdings)
• Syneos Health
• WuXi AppTec
• Lonza Group
• Piramal Pharma Solutions
• SGS SA
• Evotec SE
• CMC Biologics (Now AGC Biologics)

The detailed segments and sub-segment of the market are explained below:

By Service Type:

• Contract Research Organizations (CROs)
• Contract Development and Manufacturing Organizations (CDMOs)

By Indication:

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Others

By Therapy:

• Cell Therapy
• Gene Therapy
• RNA-based Therapies
• Others

By Phases:

• Preclinical Services
• Clinical Services
• Commercial Manufacturing and Packaging

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Executive Summary

• 1.1. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Service Type
  • 1.3.2. By Indication
  • 1.3.3. By Therapy
  • 1.3.4. By Phases
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Complexity of Advanced Therapeutic Modalities
  • 3.1.2. Growing Pipeline of Advanced Therapeutic Products
  • 3.1.3. Globalization of Clinical Trials
• 3.2. Market Challenges
  • 3.2.1. Complex and Evolving Regulatory Landscape
  • 3.2.2. High Cost of Advanced Therapeutics
• 3.3. Market Opportunities
  • 3.3.1. Expanding Landscape of mRNA Therapies
  • 3.3.2. Increasing Demand for Integrated Solutions

Chapter 4. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecasts by Service Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Advanced Therapeutics Pharmaceutical Outsourcing Market: Service Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 5.2.1. Contract Research Organizations (CROs)
  • 5.2.2. Contract Development and Manufacturing Organizations (CDMOs)

Chapter 6. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Advanced Therapeutics Pharmaceutical Outsourcing Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 6.2.1. Oncology
  • 6.2.2. Neurology
  • 6.2.3. Cardiology
  • 6.2.4. Infectious Diseases
  • 6.2.5. Others

Chapter 7. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecasts by Therapy 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Advanced Therapeutics Pharmaceutical Outsourcing Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 7.2.1. Cell Therapy
  • 7.2.2. Gene Therapy
  • 7.2.3. RNA-based Therapies
  • 7.2.4. Others

Chapter 8. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecasts by Phases 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Advanced Therapeutics Pharmaceutical Outsourcing Market: Phases Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 8.2.1. Preclinical Services
  • 8.2.2. Clinical Services
  • 8.2.3. Commercial Manufacturing and Packaging

Chapter 9. Global Advanced Therapeutics Pharmaceutical Outsourcing Market Size & Forecasts by Region 2022-2032

• 9.1. North America Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.1.1. U.S. Advanced Therapeutics Pharmaceutical Outsourcing Market
    • 9.1.1.1. Service Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Indication breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Therapy breakdown size & forecasts, 2022-2032
    • 9.1.1.4. Phases breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Advanced Therapeutics Pharmaceutical Outsourcing Market
• 9.2. Europe Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.1. UK Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.2. Germany Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.3. France Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.4. Spain Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.5. Italy Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.2.6. Rest of Europe Advanced Therapeutics Pharmaceutical Outsourcing Market
• 9.3. Asia-Pacific Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.1. China Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.2. India Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.3. Japan Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.4. Australia Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.5. South Korea Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.3.6. Rest of Asia Pacific Advanced Therapeutics Pharmaceutical Outsourcing Market
• 9.4. Latin America Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.4.1. Brazil Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.4.2. Mexico Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.4.3. Rest of Latin America Advanced Therapeutics Pharmaceutical Outsourcing Market
• 9.5. Middle East & Africa Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.5.1. Saudi Arabia Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.5.2. South Africa Advanced Therapeutics Pharmaceutical Outsourcing Market
  • 9.5.3. Rest of Middle East & Africa Advanced Therapeutics Pharmaceutical Outsourcing Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Croda International Plc
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Charles River Laboratories International, Inc.
  • 10.3.3. Catalent, Inc.
  • 10.3.4. QuintilesIMS (IQVIA)
  • 10.3.5. Parexel International Corporation
  • 10.3.6. ICON plc
  • 10.3.7. PPD, Inc. (Thermo Fisher Scientific)
  • 10.3.8. LabCorp (Laboratory Corporation of America Holdings)
  • 10.3.9. Syneos Health
  • 10.3.10. WuXi AppTec
  • 10.3.11. Lonza Group
  • 10.3.12. Piramal Pharma Solutions
  • 10.3.13. SGS SA
  • 10.3.14. Evotec SE
  • 10.3.15. CMC Biologics (Now AGC Biologics)

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes